Advertisement

Topics

Latest "Alembic Limited" News Stories

22:47 EDT 16th October 2018 | BioPortfolio

Here are the most relevant search results for "Alembic Limited" found in our extensive news archives from over 250 global news sources.

More Information about Alembic Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alembic Limited for you to read. Along with our medical data and news we also list Alembic Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alembic Limited Companies for you to search.

Showing "Alembic Limited" News Articles 1–25 of 387

Relevant

Alembic gets FDA nod for Acyclovir ointment

Alembic Pharma's abbreviated new drug application for Acyclovir ointment USP, 5% was approved by the FDA for immunocompromise -More- 


Alembic Pharmaceuticals net up by 36% in Q1

Alembic Pharmaceuticals, a Vadodara based Rs.3,100 crore plus pharma major, has posted net profit growth of 35.7 per cent during the first quarter ended June 2018 to Rs.90.47 crore from Rs.66.67 crore in the

FDA approves Alembic's major depressive disorder tablets

The FDA has approved Indian drugmaker Alembic Pharmaceuticals' abbreviated new drug application for major depressive disorder -More- 


Indian Tax Turbulence Dents Alembic In Q1 - Portends Industry Trend?

Alembic Pharmaceuticals’ first quarter earnings were weighed down by transitional disturbances pertaining to India’s new Goods and Services Tax (GST)...    

Alembic gains FDA tentative approval for generic Latisse

Alembic gets tentative FDA nod for generic Brilinta tablets

FDA approves Alembic’s generic Wellbutrin

Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy

Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.   

Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance

Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's...  

Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive...   

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET, in New York, NY. At the event, Franz Walt, Chief Executive Officer of Quotient Limited, along with other members of the management team, will provide a briefing on ...

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials. “I am very pleased to announce the start of our European field trials for...

Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim ...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of...

Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

Field trial concordance data exceed targeted criteriaPlanned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria ...

Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canad...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd, 2018 at 4:00 p.m. EDT at The InterContinental New York Barclay Hotel, in New York, NY.  ...

BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited

CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it attended a hearing before the Listing Committee of the Stock Exchange of Hong Kong Limited (“HKEx...

Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, July 24, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018, will be released after market close on Monday, August 6, 2018. Quotient will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. Eastern Time to discuss its f...

Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

MELBOURNE, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). The Agreement pr...

Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

MELBOURNE, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development & operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China vi...

Probably Relevant

Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility

Initial IH CE mark submission has been completed and filed on scheduleSuccessful facility audits pave the way for an on time BioCampus ramp up JERSEY, Channel Islands, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i) the submission of its completed dossier for the CE mark of its initial MosaiQ IH product as planned; ...

Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 15, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, will be released before market open on Tuesday, May 29, 2018. The Company will host a conference call to discuss its fourth quarter and fiscal full year financia...

Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ™ European Field Trials

MosaiQ European field trial which commenced on May 17, 2018 is ongoingFranz Walt is appointed as Chief Executive OfficerFourth quarter product revenues of $6.1 million, up 29.6% JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercialization of MosaiQ and financial resul...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks